%0 Journal Article
%T COVID-19 Vaccine Related Hyperosmolar Hyperglycemic State and Normalized Glycemia within 2 Months
%A Subhashini Yaturu
%A Somayeh D. Azimi
%A Amy M. Allen
%A John Atkins
%J Journal of Diabetes Mellitus
%P 12-17
%@ 2160-5858
%D 2022
%I Scientific Research Publishing
%R 10.4236/jdm.2022.121002
%X To protect from COVID-19 pandemic, several vaccines were developed infection with expected immunity against a SARS-CoV-2 infection. Short time side effects are reported. New onset diabetes was reported after SARS-CoV-2 infection. Here we report a case of new onset diabetes presenting with hyperosmolar hyperglycemic state, whose symptoms followed right after the second dose of Pfizer-BioNTech COVID-19 Vaccine. He is a 56-year old, obese Afro-American Veteran with no family history of diabetes and with HbA1C of 5.6 forty-five days prior to the hospitalization. He noted polyurea and excessive thirst following the second dose Pfizer-BioNTech COVID-19 vaccine. Hospitalized with hyperosmolar state and HbA1C of more than 14, he was treated initially with insulin drip and changed to basal, bolus regimen. In addition, he had new onset of oral thrush, requiring antifungal therapy. He needed higher doses of insulin during hospitalization and at discharge. He rapidly recovered and could be tapered off insulin in 4 months and recovered to normal glycemic state. We conclude that this is the second state to present with hyperosmolar state, and first case with rapid recovery of glycemic state.
%K Diabetes
%K Pfizer-BioNTech COVID-19 Vaccine CAD
%K Hyperosmolar Hyperglycemic State
%K Anemia
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=113654